Enliven Therapeutics 的亏损小于预期，超出预期，其股价在 2025 年 11 月 14 日上涨了 8.5%。 Enliven Therapeutics beat earnings estimates with a smaller-than-expected loss, sending its stock up 8.5% on November 14, 2025.

Enliven治疗公司(ELVN)报告,季度损失为每股0.32美元,比预期损失0.43美元少,导致2025年11月14日星期五的库存增加8.5%,达到22.00美元。 Enliven Therapeutics (ELVN) reported a quarterly loss of $0.32 per share, beating the expected loss of $0.43, leading to an 8.5% stock rise to $22.00 on Friday, November 14, 2025. 该公司在第一阶段试验中开发癌症治疗ELVN-001和ELVN-002,市场上限为12.9亿美元,机构所有权为95.08%。 The company, developing cancer treatments ELVN-001 and ELVN-002 in Phase 1 trials, has a market cap of $1.29 billion and 95.08% institutional ownership. 尽管90天内内部销售了近10万股,价值超过200万美元,但股票仍具有“机动购买”共识评级,目标为41.20美元。 Despite insider sales of nearly 100,000 shares worth over $2 million in 90 days, the stock holds a "Moderate Buy" consensus rating with a $41.20 target.